Artificial intelligence company Brainomix has claimed FDA approval for e-Lung, which assists in the diagnosis and assessment of patients with interstitial lung diseases (I
Amgen has doubled its range of bispecific T-cell engager (BiTE) drugs with the FDA approval of tarlatamab for advanced small cell lung cancer (SCLC) after a priority revie
Bristol-Myers Squibb has chalked up another FDA approval for its CD19-directed CAR-T therapy Breyanzi, this time as a third-line or later therapy for follicular lymphoma (
Legislation that would restrict US organisations from contracting with some Chinese biotech providers has been passed by a House of Representatives committee, moving close
Five home-testing devices for obstructive sleep apnoea hypopnoea syndrome (OSAHS), a potentially dangerous condition affecting 2.5 million adults in the UK, have been reco
Eisai and Biogen have filed a rolling biologics license application in the US for a subcutaneous formulation of Alzheimer’s disease therapy Leqembi that was delayed by the